
2800 Plymouth Rd, Bldg 16, Rm 109E
Ann Arbor, MI 48109-2800
Available to mentor

Lindsey Herrel MD, MS is a practicing urologic oncologist at the University of Michigan. She is a graduate of the Saint Louis University School of Medicine and completed her residency in urology at Emory University. She received a Master’s of Science in Health and Health Care Research at the University of Michigan where she completed a fellowship in Urologic Oncology and Health Services Research. Her clinical interests focus on the care of patients with urologic malignancies, including cancers of the kidney, testis, prostate, bladder, adrenal gland and penis. Her primary areas of research interest focus in health policy and include understanding the impact of payment reform for safety net hospitals and vulnerable populations.
-
FellowshipUniversity of Michigan–Ann Arbor, Ann Arbor, 2017
-
ResidencyEmory University, Atlanta, 2014
-
Center MemberRogel Cancer Center
-
Center MemberInstitute for Healthcare Policy and Innovation
Dr. Herrel’s research focuses on population-based analyses to assess and anticipate the impact of healthcare reform on safety net hospitals and vulnerable or underserved populations. She also has research interests in understanding how organizational structure within a health system (e.g. Accountable Care Organizations) impacts delivery of care.
-
Srivastava A, Kaufman S, Liu X, Maganty A, Shay A, Oerline M, Dall C, Faraj K, Leick S, Guro P, Hill D, Nguyen T, Herrel L, Hollenbeck B, Shahinian V. Journal of Urology, 2025 Apr 10; 213 (5S): e216Journal ArticleIP04-16 INCREASED PRACTICE-LEVEL MEDICARE ADVANTAGE PENETRATION MAY INCREASE TREATMENT IN TRADITIONAL MEDICARE BENEFICIARIES WITH PROSTATE CANCER
DOI:10.1097/01.ju.0001109780.20015.87.16 -
Srivastava A, Kaufman SR, Liu X, Maganty A, Shay A, Oerline M, Dall C, Faraj KS, Guro P, Hill D, Nguyen T, Herrel LA, Hollenbeck BK, Shahinian VB. Cancer Medicine, 2025 Mar 1; 14 (6):Journal ArticleSpillover Effects of Medicare Advantage on Traditional Medicare Beneficiaries With Prostate Cancer
DOI:10.1002/cam4.70796 PMID: 40111071 -
Dhir A, Maganty A, Stensland KD, Herrel LA, Sekar RR. Urologic Oncology Seminars and Original Investigations, 2025 Mar 1; 43 (3): 10Journal ArticleTHE ASSOCIATION BETWEEN RACE/ETHNICITY AND TRUST IN SOURCES OF CANCER INFORMATION IN PATIENTS WITH UROLOGIC CANCERS
DOI:10.1016/j.urolonc.2024.12.027 -
Sekar RR, Zebib L, Stensland KD, Herrel LA. J Natl Cancer Inst, 2025 Feb 26;Journal ArticleStructural inequities in the availability of prostate cancer clinical trial opportunities.
DOI:10.1093/jnci/djaf047 PMID: 40036373 -
Sekar RR, Maganty A, Stensland KD, Herrel LA. JCO Oncology Practice, 2025 Feb 1; 21 (2): 235 - 244.Journal ArticleAssociation of Community-Level Social Vulnerability with Clinical Trial Discussion and Participation among Cancer Survivors
DOI:10.1200/OP.24.00206 PMID: 39208361 -
Krischak MK, Nam CS, Luckenbaugh AN, Herrel LA. Cancer, 2025 Jan 1; 131 (1):Journal ArticleGender equity in oncology: Progress, challenges, and the path forward in urologic oncology and oncologic specialties
DOI:10.1002/cncr.35690 PMID: 39748457 -
Iannarino N, Francis-Levin N, Corrao J, Stelmak D, Tan CY, Ellman E, Zhang A, Herrel L, Moravek M, Chugh R, Walling E, Zebrack B. Journal of Communication in Healthcare, 2024 Dec 12;Journal ArticleExperts of their own experience: adolescent and young adult cancer patients’ advice-giving as a coping mechanism
-
Krischak M, Semerjian, MD A, Piatt G, Landis-Lewis Z, Barnes G, Lewicki P, Morgan T, Caram M, Herrel L, Sales A, Skolarus T, Stensland K. 2024 Dec 4;Proceeding / Abstract / PosterARE WOMEN UNDERREPRESENTED IN UROLOGIC ONCOLOGY CLINICAL TRIALS?